Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin for the treatment of sickle cell disease, and company updates commonly address PIONEER trial data, markers of hemolysis and anemia, and sickle cell disease collaborations.
FULC news also covers quarterly financial results, corporate presentations, Nasdaq inducement equity grants, board composition, and updates to the company's pipeline and financial position as it advances small molecules that modulate gene expression.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) has successfully closed its public offering of 4,600,000 shares at $11.00 each, generating total gross proceeds of $50.6 million. This offering included 600,000 shares from underwriters exercising their option to purchase additional shares. The company aims to utilize these funds to advance its clinical trials for treatments targeting genetically defined rare diseases, including facioscapulohumeral muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics has announced a public offering of 4,000,000 shares of its common stock at $11.00 each, totaling gross proceeds of $44 million, before expenses. The offering is fully underwritten and expected to close on January 22, 2021. Additionally, the underwriters have a 30-day option to purchase up to 600,000 more shares. The offering is registered under an effective shelf registration statement with the SEC. Funds from this offering will support the company's clinical programs for rare diseases.
Fulcrum Therapeutics (Nasdaq: FULC) announced the commencement of an underwritten public offering of its common stock, entirely offered by the company. The offering will include a 30-day option for underwriters to purchase an additional 15% of the shares. This follows a previously filed shelf registration statement with the SEC. Joint book-running managers for the offering include SVB Leerink, Piper Sandler & Co., and Credit Suisse. The completion of the offering is subject to market conditions, and there is no assurance regarding its final terms.
Fulcrum Therapeutics (Nasdaq: FULC) has promoted Christopher Moxham, Ph.D. to chief scientific officer, effective February 5, 2021. He will lead the company’s drug discovery and translational science efforts, including advancing FTX-6058 for sickle cell disease and beta thalassemia. Owen Wallace, Ph.D., the previous CSO, will transition to the Scientific Advisory Board, contributing his expertise to ongoing R&D. Moxham brings over 20 years of experience in drug discovery, previously at Eli Lilly, and is expected to enhance Fulcrum's pipeline development.
Fulcrum Therapeutics (Nasdaq: FULC), a biopharmaceutical company focused on rare diseases, announced management's participation in a fireside chat at the virtual H.C. Wainwright BioConnect Conference. The live webcast will be accessible on January 11, 2021, at 6:00 a.m. ET through the conference portal and the company's investor relations site. An archived replay will be available for 90 days post-conference. Fulcrum is advancing treatments such as losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease in clinical development.
Fulcrum Therapeutics (Nasdaq: FULC) announced a Key Opinion Leader (KOL) meeting on December 15, 2020, at 8:30 am ET to present their novel compound FTX-6058 targeting hemoglobinopathies, specifically sickle cell disease and beta-thalassemia.
Prominent experts, including Dr. Maureen Achebe and Dr. Gerd Blobel, will discuss the treatment landscape and answer questions. FTX-6058 is a small molecule designed to increase fetal hemoglobin expression, with promising preclinical results showing a potential 30% increase in HbF levels. A Phase 1 trial in healthy volunteers is underway.
Fulcrum Therapeutics (Nasdaq: FULC) announced the presentation of preclinical data on FTX-6058 for sickle cell disease during the virtual 62nd ASH Annual Meeting, December 5-8, 2020. FTX-6058, a potent EED inhibitor, showed potential to increase fetal hemoglobin (HbF) by approximately 30% in preclinical models, potentially transforming sickle cell treatment. The company has also initiated a Phase 1 trial with FTX-6058 in healthy volunteers. The robust pharmacological profile and mechanism of action could address significant unmet needs in sickle cell disease.
Fulcrum Therapeutics (Nasdaq: FULC) announced participation in two upcoming virtual investor conferences. The Stifel Virtual 2020 Healthcare Conference is scheduled for November 18, 2020, at 11:20 a.m. ET, while the Piper Sandler 32nd Annual Virtual Healthcare Conference will feature a prerecorded fireside chat on November 23, 2020, at 10:00 a.m. ET. Audio webcasts will be accessible on their Investor Relations website, with archived replays available for 90 days. Fulcrum focuses on addressing genetically defined rare diseases and is advancing several clinical programs.
Fulcrum Therapeutics, Inc. (FULC) provided a business update and financial results for Q3 2020, highlighting significant progress with clinical trials and management appointments. The full data from the ReDUX4 trial with losmapimod in FSHD is expected in 2Q 2021, with encouraging interim results. Phase 1 trial with FTX-6058 for sickle cell disease is on track for dosing by year-end 2020. With cash reserves of $127 million, the company expects to fund operations into 2Q 2022. Net loss for Q3 was $19 million, compared to $16.5 million in the previous year.
Fulcrum Therapeutics (Nasdaq: FULC) has initiated the screening of healthy volunteers in its Phase 1 clinical trial for FTX-6058, a small molecule aimed at treating sickle cell disease and β-thalassemia. The company will also present preclinical data on FTX-6058 at the upcoming ASH Annual Meeting from December 5-8, 2020. Preclinical studies indicate potential elevations of fetal hemoglobin by up to 30%. The results will support the ongoing clinical trial, highlighting FTX-6058's promise for addressing hemoglobinopathies.